American Renal Associates Holdings Inc (ARA) Gets a Buy Rating from SunTrust Robinson

SunTrust Robinson analyst David S Macdonald reiterated a Buy rating on American Renal Associates Holdings Inc (ARA) on November 12 and set a price target of $22. The company’s shares closed yesterday at $16.01.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 16.3% and a 73.1% success rate. Macdonald covers the Services sector, focusing on stocks such as Walgreens Boots Alliance, WellCare Health Plans, and Tenet Healthcare.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for American Renal Associates Holdings Inc with a $24 average price target.

See today’s analyst top recommended stocks >>

Based on American Renal Associates Holdings Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $2.01 million. In comparison, last year the company had a net profit of $7.99 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

American Renal Associates Holdings, Inc. operates with interest in providing kidney dialysis services. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure.